TRANSCAN-2

Cancer is a worldwide health burden and represents a major public health challenge in Europe. Today, an estimated 9 million individuals in Europe live with cancer, contributing to the ongoing increase in medical expenditures, and accordingly posing a major socio-economic challenge for the EU. Translational research applies knowledge from basic biology and clinical trials to techniques and tools that address critical medical needs to reduce cancer incidence and mortality rates and improve the quality of life of patients and overall health outcomes. TRANSCAN-2 aligns national and regional translational cancer research programmes and activities to link translational cancer research funding programmes. This avoids duplication of efforts and ensures more efficient use of available resources.

ECPC sits on the project’s Scientific Advisory Board to ensure the project activities are in line with the needs of cancer patients, actively participating in discussions with ministries, funding agencies and research councils on translational cancer research programmes, and extending the cooperation through the exchange of information, harmonisation of funding mechanisms and assessment of results from the research projects funded.